Menu
Articles
Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.
Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, …
Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.
BioWorld, David Ho, March 2021.
Technology Networks, Ryan Sullivan, Wugen, March 2021
St. Louis Business Journal, Nathan Rubbelke, March 2021
St. Louis Business Journal, Nathan Rubbelke, February 2021
Biospace, Kate Goodwin, January 2021
Latest News
— Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study …
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability …
— WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS …
Next in our story
Copyright © 2023 Wugen. All Rights Reserved.
a COGNEO design